- Home
- CTMX vs ZBIO Comparison
CTMX vs ZBIO Comparison
Compare CTMX & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ZBIO
- Stock Information
- Founded
- CTMX 2008
- ZBIO 2019
- Country
- CTMX United States
- ZBIO United States
- Employees
- CTMX N/A
- ZBIO N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- CTMX Health Care
- ZBIO
- Exchange
- CTMX Nasdaq
- ZBIO NYSE
- Market Cap
- CTMX 378.1M
- ZBIO 389.2M
- IPO Year
- CTMX 2015
- ZBIO 2024
- Fundamental
- Price
- CTMX $2.64
- ZBIO $11.12
- Analyst Decision
- CTMX Strong Buy
- ZBIO Strong Buy
- Analyst Count
- CTMX 2
- ZBIO 7
- Target Price
- CTMX $5.00
- ZBIO $32.29
- AVG Volume (30 Days)
- CTMX 11.3M
- ZBIO 135.6K
- Earning Date
- CTMX 05-12-2025
- ZBIO 06-17-2025
- Dividend Yield
- CTMX N/A
- ZBIO N/A
- EPS Growth
- CTMX 128.27
- ZBIO N/A
- EPS
- CTMX 0.49
- ZBIO N/A
- Revenue
- CTMX $147,557,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- CTMX N/A
- ZBIO $206.00
- Revenue Next Year
- CTMX N/A
- ZBIO $77.40
- P/E Ratio
- CTMX $5.44
- ZBIO N/A
- Revenue Growth
- CTMX 23.81
- ZBIO N/A
- 52 Week Low
- CTMX $0.40
- ZBIO $5.83
- 52 Week High
- CTMX $2.82
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- CTMX 67.47
- ZBIO N/A
- Support Level
- CTMX $2.35
- ZBIO N/A
- Resistance Level
- CTMX $2.75
- ZBIO N/A
- Average True Range (ATR)
- CTMX 0.25
- ZBIO 0.00
- MACD
- CTMX -0.01
- ZBIO 0.00
- Stochastic Oscillator
- CTMX 78.82
- ZBIO 0.00
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.